Use of trypsin-modified human erythrocytes in rubella hemagglutination-inhibition testing.
A method of treating human erythrocytes with trypsin has been modified and found to be an efficient and practical indicator system for the rubella hemagglutination-inhibition test. Both the trypsin-treated human cells and the widely used, newborn chicken erythrocytes were used in comparative testing of 464 selected diagnostic rubella serums. Results with each cell system were essentially the same. The trypsin treatment procedure has been found to be relatively simple, and with our limited testing has not presented any problems with reproducibility. Other advantages include the ready availability of human cells, greater intralaboratory standardization of the test by using the same donors over a long period of time, and elimination of adsorption of test sera with red blood cells.
D000017:ABO Blood-Group System; D000328:Adult; D000818:Animals; D000831:Animals, Newborn; D000956:Antigens, Viral; D002645:Chickens; D003298:Coombs Test; D003937:Diagnosis, Differential; D004912:Erythrocytes / Q000276:immunology*; D005069:Evaluation Studies as Topic; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007106:Immune Sera; D008722:Methods; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System; D012409:Rubella / Q000175:diagnosis*; D012412:Rubella virus / Q000276:immunology*; D012698:Serologic Tests; D014357:Trypsin
D000017:ABO Blood-Group System; D000956:Antigens, Viral; D007106:Immune Sera; D012204:Rh-Hr Blood-Group System; D014357:Trypsin